Drug recall · February 19, 2020
Ethacrynate Sodium for Injection recall
Why: cGMP Deviations
Class II: could cause temporary or reversible health problems; serious harm is remote.
The recall
- Product
Ethacrynate Sodium for Injection, USP, 50mg/vial, Single Dose Vial, Rx Only, Manufactured by: Cadila Healthcare Limited, Ahmedabad, India, Distributed by: Zydus Pharmaceuticals (USA) Inc., Pennington, NJ 08534, NDC 68382-246-01.
- Lots / codes
Lot #s: M804062, Exp. 01/2020; M804063, M804064, Exp. 02/2020
- Quantity
- 2207 Vials
- Company
- Zydus Pharmaceuticals USA Inc, Pennington, NJ
- Distribution
- Nationwide in the U.S.
- Initiated
- January 31, 2020 · Voluntary: Firm initiated
- Classified
- February 10, 2020
- Reported
- February 19, 2020
- Ended
- October 26, 2021
- How notified
- Letter
The drug: prices, other makers, shortages
If you have this product
- Check the lot number on your package against the lots above. Only those lots are recalled.
- Don't stop a prescription medicine on your own. Call your pharmacy - they can swap it for an unaffected lot or another maker.
- Felt unwell? Contact your doctor, and report it to FDA MedWatch (1-800-FDA-1088 or fda.gov/medwatch).
- Return or dispose of recalled product as the company or your pharmacy advises.
Questions about this recall
No comments yet. Questions, tips, what worked for you - start the conversation.
Watch Ethacrynate
One email when the price moves, a recall or shortage is posted, or the label changes. Plus the monthly biggest-movers report. Unsubscribe in one click.